A deep dive into the implications of the Replimune CRL that surprised insiders and investors, the role of new leadership at ...

The Revell family hoped a gene therapy could buy time for their sons, who have a rare and fatal disease. After two patients died, the drug’s manufacturer halted dosing under pressure from the FDA.